Treatment of uncomplicated falciparum malaria in Bobo-Dioulasso, Burkina Faso: comparison of artemether/lumefantrine, dihydroartemisinin/piperaquine, and amodiaquine/sulfadoxine-pyrimethamine

ISRCTN ISRCTN94367569
DOI https://doi.org/10.1186/ISRCTN94367569
Secondary identifying numbers N/A
Submission date
09/02/2007
Registration date
24/04/2007
Last edited
23/09/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Ouedraogo Jean Bosco
Scientific

399, Avenue de la Liberte
PO BOX: 545
Bobo-Dioulasso
-
Burkina Faso

Phone +226 20 981880
Email jbouedraogo.irss@fasonet.bf

Study information

Study designRandomized, single-blind trial.
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeNot Specified
Scientific titleTreatment of uncomplicated falciparum malaria in Bobo-Dioulasso, Burkina Faso: comparison of artemether/lumefantrine, dihydroartemisinin/piperaquine, and amodiaquine/sulfadoxine-pyrimethamine
Study objectivesWe hypothesize that Artemether/Lumefantrine (AL) and Dihydroartemisinin/Piperaquine (DP), each of which is a promising new artemisinin-based combination antimalarial therapy, and Amodiaquine/Sulfadoxine-Pyrimethamine (AQ/SP), an older regimen, will provide outstanding and equivalent efficacy for the treatment of uncomplicated malaria. To test this hypothesis, our aim will be to compare the antimalarial efficacy of these three regimens. The study will be a randomized comparison at three sites in Bobo-Dioulasso. A secondary aim will be to compare the safety and tolerability of the study regimens.
Ethics approval(s)1. UCSF committee on Human Research (California, USA), approved on 25 July 2006. Ref: CHR # H2397-29335-01
2. Centre Muraz / IRSS Institutional Review Board (Burkina Faso), approved in July 2006. Ref: 012-2006/CE-CM
Health condition(s) or problem(s) studiedMalaria
InterventionThis trial compares three therapies for uncomplicated malaria, conducted at three locations in the city of Bobo-Dioulasso, Burkina Faso. The design will closely follow two studies that we conducted in 2004 and 2005 in Burkina Faso (UCSF CHR H2397-25259 and H2397-27158) following guidelines of the World Health Organization (WHO) for assessment of therapeutic efficacy of antimalarial agents in areas of intense transmission, with slight modifications. The target population is residents of three catchment areas within Bobo-Dioulasso, with care at dispensaries at Sarfalao, Colsama and Ouezzin-ville. The available population is residents aged 6 months and older who present to one of the study clinics with symptoms suggestive of malaria and who have a positive screening thick blood smear. Subjects who meet the inclusion criteria and are enrolled in the trial will be randomized to treatment with one of the three study regimens and will be followed for 42 days. The study regimens will be AL (Coartem), DP (Duocotexcin), and AQ/SP, each administered for three days. Repeat evaluations will be performed on days 1, 2, 3, 7, 14, 21,28, 35 and 42 and will include assessment for the occurrence of any serious adverse events. Treatment efficacy outcomes will be assessed using modifications of WHO clinical and parasitological classification criteria.

Patients will be randomized to receive:
1. Artemether-lumefantrine (Novartis, 20 mg artemether/120 mg lumefantrine tablets, 1 [5 - 14 kg], 2 [15 - 24 kg], 3 [25 - 34 kg], or 4 [> 35 kg] tablets twice daily for 3 days) or
2. Amodiaquine (Parke-Davis, 200 mg tablets, 10 mg/kg on days 0 and 1, and 5 mg/kg on day 2) + sulfadoxine-pyrimethamine (Roche, 25 mg/kg of sulfadoxine and 1.25 mg/kg pyrimethamine administered on day 0) or
3. Dihydroartemisinin/piperaquine once daily for 3 days in the morning given in fixed dose tablets (40 mg dihydroartemisinin + 320 mg piperaquine) according to weight-based guidelines consisting of a total dose of 6.4 and 51.2 mg/kg of dihydroartemisinin and piperaquine, respectively.
Intervention typeOther
Primary outcome measurePrimary outcomes will be based on the risk of clinical and parasitological treatment failure after 28 days of follow-up either adjusted or unadjusted
Secondary outcome measures1. Risk of clinical failure after 14 days of follow-up
2. Risk of rescue therapy after 42 days of follow-up
3. Risk of fever during the first 3 days of follow-up: presence or absence of objective fever (axillary temperature > 37.5°C) or patient report of fever on days 1, 2, 3
4. Risk of parasitemia on follow-up days 2 and 3: proportion of positive vs. negative thick blood smears on day 2 and day 3
5. Change in mean hemoglobin from day 0 to 42 or day of repeat therapy
6. Proportion gametocytemic: presence vs. absence of gametocytes on any follow-up thick blood smear; proportion gametocytemic on days 2, 3, 7, 14, 21, 28, 35 and 42
7. Risk of serious adverse events: proportion of patients experiencing any serious adverse event in each treatment group during the 42-day follow-up period, excluding treatment failures
8. Risk of adverse events of moderate or greater severity, at least possibly related to the study medications, excluding treatment failures
Overall study start date01/08/2006
Completion date31/01/2007

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participants528
Key inclusion criteria1. Age 6 months and above
2. Fever (> 37.5ºC axillary) or history of fever in the previous 24 hours
3. Absence of any history of serious side effects to study medications, including allergy to sulfa drugs
4. No evidence of a concomitant febrile illness in addition to malaria
5. Provision of informed consent and ability to participate in 42-day follow-up (patient has easy access to health unit)
6. No history of treatment with any antimalarial (other than chloroquine) in the past 2 weeks.
7. No danger signs or evidence of severe malaria defined as:
7.1 Unarousable coma (if after convulsion, > 30 min)
7.2 Repeated convulsions (> 2 within 24 h)
7.3 Recent convulsions (1-2 within 24 h)
7.4 Altered consciousness (confusion, delirium, psychosis, coma)
7.5 Lethargy
7.6 Unable to drink or breast feed
7.7 Vomiting everything
7.8 Unable to stand/sit due to weakness
7.9 Severe anemia (hemoglobin < 5.0 g/dL)
7.10 Respiratory distress (labored breathing at rest)
7.11 Jaundice (yellow coloring of eyes)

Patients fulfilling these criteria will be assigned a study number and referred to the study nurse for treatment allocation and treatment with the study medications. Patients must also meet the following criterion:
8. Absence of repeated vomiting of study medications on day 0

After treatment with the study medications, patients will be referred to the laboratory. A fingerprick blood sample will be obtained to prepare thick and thin blood smears, and for measurement of hemoglobin. Patients will be excluded from the study on day 1 if the following inclusion criteria are not met.
9. P. falciparum mono-infection
10. Parasite density > 2000/ul and < 200,000/ul
11. Hemoglobin > 5.0 g/dL
Key exclusion criteria1. Signs of severe malaria/danger signs
2. Known Allergy to the study medications
3. Inability to participate in 42 days follow up
4. Concommittant febrile illness
5. Severe anemia < 5g/dL
6. Absence of provision of informed and signed consent
7. Previous antimalarial use (other than chloroquine [CQ]) in the previous 14 days
8. Mixed infection
Date of first enrolment01/08/2006
Date of final enrolment31/01/2007

Locations

Countries of recruitment

  • Burkina Faso

Study participating centre

399, Avenue de la Liberte
Bobo-Dioulasso
-
Burkina Faso

Sponsor information

Institut de Recherche en Science de la Sante (IRSS) (Burkina Faso)
Government

399 Avenue de la Liberte
PO BOX: 545
Bobo-Dioulasso
-
Burkina Faso

ROR logo "ROR" https://ror.org/05m88q091

Funders

Funder type

Charity

Doris Duke Charitable Foundation (USA)
Private sector organisation / Trusts, charities, foundations (both public and private)
Alternative name(s)
Doris Duke Charitable Foundation, Inc., DDCF Trust, Doris Duke Foundation, DDCF
Location
United States of America
Beijing Holley-Cotec Pharmaceuticals Co. Ltd (China)

No information available

International Atomic Energy Agency (Austria)
Private sector organisation / International organizations
Alternative name(s)
IAEA
Location
Austria
National Budget of Institut de Recherche en Science de la Sante (IRSS)/ Direction Regionale de l'Ouest (DRO) (Burkina Faso)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 01/12/2007 23/09/2021 Yes No

Editorial Notes

23/09/2021: Publication reference added.